UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002479
Receipt number R000003014
Scientific Title Identifing medical predictors of anti-hypertensive effect of eplerenone
Date of disclosure of the study information 2009/09/11
Last modified on 2017/09/15 13:30:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Identifing medical predictors of anti-hypertensive effect of eplerenone

Acronym

IMPRESSIVE Study

Scientific Title

Identifing medical predictors of anti-hypertensive effect of eplerenone

Scientific Title:Acronym

IMPRESSIVE Study

Region

Japan


Condition

Condition

Hypertension

Classification by specialty

Medicine in general

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To identify predictors of anti-hypertensive effect of eplerenone, which is a selective mineralocorticoid receptor antagonist, among clinical parameters.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Correlation between aldosterone/renin ratio before administration of eplerenone and anti-hypetensive effect.

Key secondary outcomes

Correlation between other parameters, which include BMI, waist circumference, gender, urinary Na excretion, urinary aldosterone, urinary free cortisol, renal 11beta-hydroxysteroid dehydrogenase activity, serum K, creatinine, ANP, BNP, and urinary 8OHdG, and anti-hypetensive effect.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administer 50mg of eplerenone for one month and check blood pressure. For another month upscale 50mg to 100mg of eplerenone and re-check anti-hypertensive effect.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patient with high blood pressure (systolic BP>140mmHg and/or diastolic BP>90mHg)

Key exclusion criteria

1. renal dysfunction (eGFR<50ml/min or male Cr>2.0mg/dl, female Cr>1.8mg/dl)
2. liver dysfunction
3. serum K>5.0mEq/l before intervention
4. diabetes

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hirotaka Shibata

Organization

School of Medicine, Keio University

Division name

Internal Medicine

Zip code


Address

35 Shinanomachi, Shinjuku-ku, Tokyo, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Hirotaka Shibata

Organization

School of Medicine, Keio University

Division name

Internal Medicine

Zip code


Address


TEL


Homepage URL


Email

hiro-405@cb3.so-net.ne.jp


Sponsor or person

Institute

Department of Internal Medicine, School of Medicine, Keio University

Institute

Department

Personal name



Funding Source

Organization

Pfizer Japan Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 09 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2009 Year 04 Month 01 Day

Date of IRB


Anticipated trial start date

2009 Year 09 Month 01 Day

Last follow-up date

2017 Year 06 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 09 Month 10 Day

Last modified on

2017 Year 09 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003014


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name